Berris van Kessel

CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma

Inger S. Nijhof, Tineke Casneuf, Jeroen van Velzen et al. · Blood · 2016 · 380 citations · Full text

Life Sciences, Immunology, Oncology +13

Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab

Inger S. Nijhof, Richard W.J. Groen, H M Lokhorst et al. · Leukemia · 2015 · 266 citations · Full text

Medicine, Immunology, Pharmacology +17

Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab

Michael S. van der Veer, Michel de Weers, Berris van Kessel et al. · Haematologica · 2010 · 217 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab

Jakub Krejcik, Kris A. Frerichs, Inger S. Nijhof et al. · Clinical Cancer Research · 2017 · 171 citations

Medicine, Immunology, Pharmacology +15

Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib

Inger S. Nijhof, Richard W.J. Groen, Willy A. Noort et al. · Clinical Cancer Research · 2014 · 149 citations

Medicine, Pharmacology, Pharmacotherapy +17